CTO East Coast (Clinical Trials in Oncology) 2024
Join the TFS HealthScience team at CTO East Coast 2024 in Boston, MA from July 9-10.
Meet our seasoned team of oncology & hematology experts attending the conference. You can stop by Booth #15 to learn how to run accelerated clinical trials efficiently and effectively!
Our oncology & hematology team excels in managing clinical development Phases I-IV and patient recruitment across multiple indications. We pride ourselves on partnering with sponsors to develop a regulatory and operational strategy tailored to your specific trial’s requirements.
Why TFS in Oncology & Hematology?
Experience scientific and medical excellence in oncology & hematology. Our team delivers all the scientific and medical aspects of your clinical program to help ensure market success. We provide support in site start-up, patient access, referral, recruitment and retention, and investigator identification at global, regional, and local levels. With our internal experts and global network of key opinion leaders (KOLs), we ensure a comprehensive approach to your dermatology trials.
Click here to learn more about our oncology & hematology services!
Our Experts
Contact us today to connect during the conference and discover how TFS can be your strategic CRO partner in oncology & hematology clinical development. See you at CTO East Coast (Clinical Trials in Oncology) 2024!
Attend Our Presentation
- July 10 at 10:00am
- Building Success Together: A Reflection on Oncology Trial Management
by Bin Pan, PHD
This presentation will use a real-life event as an analogy to explore the Sponsor’s involvement and oversight in clinical operations, focusing on strategies to maximize success.
- Balancing Involvement: How Little is Too Little and How Much is Too Much?
- Evaluating Industry Standards
- Adopting a Consultative Approach to Problem-Solving
About Our Presenter: Bin Pan, PHD
Bin Pan has 23 years of experience in clinical research with a strong focus on early-phase oncology trial strategy and execution. She has a scientific background in biochemistry and molecular biology with postdoctoral research in cellular signaling pathways.
Throughout her career, Bin has supported numerous oncology studies through an evolving therapeutic landscape from the early days of mAb drugs such as trastuzumab and cetuximab to the current immuno-oncology revolution with checkpoint inhibitors such as CAR-T and TCR-T.
She maintains a broad knowledge of current oncology therapeutics and the competitive clinical landscape. She provides strategic guidance and operational leadership to internal cross-functional teams as well as a consultative approach to developing novel solutions.